Alimta

... Millennium Reports Positive Data for VELCADE(R) (bortezomib) for Injection in Lymphoma and Lung Cancer at ASCO; Advances in MLN2704 Also Presented Millennium Reports Positive Data for VELCADE(R) (bortezomib) for Injection in Lymphoma and Lung Cancer at ASCO; Advances in MLN2704 Also Presented Results support broad development program and underscore strength of oncology pipeline ORLANDO, Fla., May 14 /PRNewswire-FirstCall/ - Millennium Pharmaceuticals, Inc.

(Nasdaq: MLNM) today announced positive results from studies of VELCADE in lymphoma and lung cancer at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place this week in Orlando, Florida.

Data for MLN2704, the Company's drug candidate for prostate cancer, were also presented.

Results included: * In relapsed patients with mantle cell lymphoma (MCL), interim results of a multicenter phase II study of single-agent VELCADE showed median survival had not been reached after 10.5 months of follow-up, and demonstrated an overall response rate of 42 percent; * In non-small cell lung cancer (NSCLC), final data from the single-agent arm of the multicenter phase II trial of VELCADE with or without docetaxel showed a response rate and overall survival comparable to approved agents for use in second-line lung cancer; and * In patients with late-stage, hormone-refractory prostate cancer, interim phase I/II results of MLN2704 showed four of six patients receiving a high dose ...

Read more...